Skip to content
The Policy VaultThe Policy Vault

Verkazia (cyclosporine 0.1% ophthalmic emulsion)United Healthcare

moderate to severe vernal keratoconjunctivitis

Preferred products

  • ophthalmic antihistamines (e.g., azelastine, olopatadine)
  • ophthalmic mast cell stabilizers (e.g., cromolyn sodium)
  • ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone)

Initial criteria

  • Diagnosis of moderate to severe vernal keratoconjunctivitis
  • AND History of failure, contraindication, or intolerance to two of the following categories: ophthalmic antihistamines (e.g., azelastine, olopatadine), ophthalmic mast cell stabilizers (e.g., cromolyn sodium), ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone)

Reauthorization criteria

  • Documentation of positive clinical response

Approval duration

12 months